共 50 条
- [1] A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Lee-Bitar, Jin SunFrankel, Paul HenryYost, Susan ElaineSynold, Timothy W.Martinez, NormaTang, AileenSchmolze, DanApple, SophiaHurria, ArtiWaisman, James RossSomlo, GeorgePatel, Niki TankSedrak, Mina S.Mortimer, Joanne E.Yuan, Yuan
- [2] A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast CancerONCOLOGIST, 2021, 26 (02): : 99 - e217Yuan, YuanLee, Jin SunYost, Susan E.Frankel, Paul H.Ruel, ChristopherEgelston, Colt A.Guo, WeihuaGillece, John D.Folkerts, MeganReining, LaurenHighlander, Sarah K.Robinson, KimPadam, SimranMartinez, NormaTang, AileenSchmolze, DanielWaisman, JamesSedrak, MinaLee, Peter P.Mortimer, Joanne
- [3] Effect of GTx-024, a selective androgen receptor modulator (SARM), on stair climb performance and quality of life (QOL) in patients with cancer cachexia.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Steiner, M. S.Barnette, K. G.Hancock, M. L.Dodson, S. T.Rodriguez, D.Morton, R. A.
- [4] Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatinInvestigational New Drugs, 2016, 34 : 458 - 467Christopher C. CossAmanda JonesJames T. Dalton
- [5] Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatinINVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 458 - 467Coss, Christopher C.Jones, AmandaDalton, James T.
- [6] A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR plus TNBC)CANCER RESEARCH, 2016, 76Rugo, H.Overmoyer, B.Schwartzberg, L.Palmieri, C.Taylor, R.Hancock, M.Small, S.Johnston, M. A.
- [7] Selective androgen receptor degraders for the treatment of androgen receptor-positive, triple-negative breast cancer.CANCER RESEARCH, 2021, 81 (13)Asemota, SarahYoung, Kirsten YoungPonnusamy, SuriyanThiyagarajan, ThirumagalHwang, Dong-JinHe, YaliBreitmeyer, James B.Kaufmann, Gunnar F.Miller, Duane D.Narayanan, Ramesh
- [8] Phase I trial of bicalutamide and ribociclib in androgen receptor- positive triple negative breast cancerCANCER RESEARCH, 2019, 79 (04)Sharifi, M.Wisinski, K. B.Burkard, M. E.Tevaarwerk, A. J.Tamkus, D.Chan, N.Truica, C.Danciu, O.Hoskins, K.O'Regan, R. M.
- [9] Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast CancerCLINICAL CANCER RESEARCH, 2013, 19 (19) : 5505 - 5512Gucalp, AycaTolaney, SaraIsakoff, Steven J.Ingle, James N.Liu, Minetta C.Carey, Lisa A.Blackwell, KimberlyRugo, HopeNabell, LisleForero, AndresStearns, VeredDoane, Ashley S.Danso, MichaelMoynahan, Mary EllenMomen, Lamia F.Gonzalez, Joseph M.Akhtar, AroojGiri, Dilip D.Patil, SujataFeigin, Kimberly N.Hudis, Clifford A.Traina, Tiffany A.
- [10] Androgen receptor in triple negative breast cancerJOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2013, 133 : 66 - 76McNamara, K. M.Yoda, T.Takagi, K.Miki, Y.Suzuki, T.Sasano, H.